search
Back to results

Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

Primary Purpose

Rotator Cuff Tear, Lateral Epicondylitis

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Autologous adipose-derived MSCs
Compound betamethasone
Sponsored by
Second Affiliated Hospital, School of Medicine, Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rotator Cuff Tear focused on measuring Adipose-drived mesenchymal stem cells, Rotator cuff injury, Lateral Epicondylitis, Randomized controlled trials

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow);
  2. symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid;
  3. patient that can understand the clinical trials and signed the informed consent.

Exclusion Criteria:

  1. patient that underwent other injection treatment within 6 weeks
  2. some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue)
  3. patient that enrolled other clinical trials within 3 months
  4. history of drug/alcohol addiction, habitual smoker

Sites / Locations

  • Weiliang Shen

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Autologous adipose-derived MSCs

Compound betamethasone

Arm Description

The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.

1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

Outcomes

Primary Outcome Measures

Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks
Pain on activity will be evaluated by VAS

Secondary Outcome Measures

Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,
Functional score of the shoulder
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Functional score of the shoulder
The Disabilities of the Arm, Shoulder and Hand(DASH) Score
Functional score of the shoulder
Adverse events
Adverse events to evaluate the safety

Full Information

First Posted
September 4, 2017
Last Updated
April 24, 2018
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators
Zhejiang Xingyue Biotechnology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03279796
Brief Title
Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells
Official Title
Autologous Adipose-derived Mesenchymal Stem Cells in the Treatment of Tendon Disease: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2018 (Anticipated)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
December 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators
Zhejiang Xingyue Biotechnology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study was a single-center, randomized, single-blind clinical trial. We plan to include 100 patients who met exclusion criteria of rotator cuff and lateral epicondylosis (tennis elbow) respectively by MRT or ultrasonography. The patients will be randomly divided into two groups. Adipose mesenchymal stem cells will be isolated from adipose tissue, cultured and then transplanted back to the tendon injury site by multiple point injection. 1*10^6 cells as an unit. Patients in the experiment group will be injected into an unit of adipose mesenchymal stem cells (1*10^6/10kg) while the control group received the same dose compound betamethasone injection. Follow up visit for all patients will occur at 1,3,6 and 12 months after the first injection. Clinical quantitative assessment will measure by the visual analogue scale(VAS). The secondary outcomes are the constant-murley score(CMS) and the rating scale of the American shoulder and elbow surgeons(ASES) and the disability of arm shoulder and hand(DASH). The objective evaluation methods is that the examination of MRI or ultrasound were accomplished before the first injection and at 6 and 12 months afterwards.
Detailed Description
All injection will be done under ultrasound guidance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotator Cuff Tear, Lateral Epicondylitis
Keywords
Adipose-drived mesenchymal stem cells, Rotator cuff injury, Lateral Epicondylitis, Randomized controlled trials

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous adipose-derived MSCs
Arm Type
Experimental
Arm Description
The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
Arm Title
Compound betamethasone
Arm Type
Active Comparator
Arm Description
1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
Intervention Type
Biological
Intervention Name(s)
Autologous adipose-derived MSCs
Intervention Description
The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
Intervention Type
Drug
Intervention Name(s)
Compound betamethasone
Intervention Description
1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
Primary Outcome Measure Information:
Title
Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks
Description
Pain on activity will be evaluated by VAS
Time Frame
Baseline, 3 weeks, 6 weeks, 12 weeks after intervention
Secondary Outcome Measure Information:
Title
Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,
Description
Functional score of the shoulder
Time Frame
Baseline, 3 weeks, 6 weeks, 12 weeks after intervention
Title
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
Description
Functional score of the shoulder
Time Frame
Baseline, 3 weeks, 6 weeks, 12 weeks after intervention
Title
The Disabilities of the Arm, Shoulder and Hand(DASH) Score
Description
Functional score of the shoulder
Time Frame
Baseline, 3 weeks, 6 weeks, 12 weeks after intervention
Title
Adverse events
Description
Adverse events to evaluate the safety
Time Frame
From baseline through study completion, an average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow); symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid; patient that can understand the clinical trials and signed the informed consent. Exclusion Criteria: patient that underwent other injection treatment within 6 weeks some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue) patient that enrolled other clinical trials within 3 months history of drug/alcohol addiction, habitual smoker
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weiliang Shen, Doctor
Phone
+86-13757101563
Email
wlshen@zju.edu.cn
Facility Information:
Facility Name
Weiliang Shen
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310058
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weiliang Shen, Doctor

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21773831
Citation
Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. Knee Surg Sports Traumatol Arthrosc. 2012 Feb;20(2):373-7. doi: 10.1007/s00167-011-1607-9. Epub 2011 Jul 20.
Results Reference
background
PubMed Identifier
22220180
Citation
Pascual-Garrido C, Rolon A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int. 2012;2012:953510. doi: 10.1155/2012/953510. Epub 2011 Dec 18.
Results Reference
background
PubMed Identifier
24913770
Citation
Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, Rouard H. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop. 2014 Sep;38(9):1811-8. doi: 10.1007/s00264-014-2391-1. Epub 2014 Jun 7.
Results Reference
background
PubMed Identifier
28077355
Citation
Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. Br J Sports Med. 2017 Jul;51(13):996-1002. doi: 10.1136/bjsports-2016-096794. Epub 2017 Jan 11.
Results Reference
background
PubMed Identifier
26202898
Citation
Lee SY, Kim W, Lim C, Chung SG. Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study. Stem Cells. 2015 Oct;33(10):2995-3005. doi: 10.1002/stem.2110. Epub 2015 Aug 6.
Results Reference
background
PubMed Identifier
12857411
Citation
Ouyang HW, Goh JC, Thambyah A, Teoh SH, Lee EH. Knitted poly-lactide-co-glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon. Tissue Eng. 2003 Jun;9(3):431-9. doi: 10.1089/107632703322066615.
Results Reference
background
PubMed Identifier
24403741
Citation
Minagawa H, Yamamoto N, Abe H, Fukuda M, Seki N, Kikuchi K, Kijima H, Itoi E. Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: From mass-screening in one village. J Orthop. 2013 Feb 26;10(1):8-12. doi: 10.1016/j.jor.2013.01.008. eCollection 2013.
Results Reference
background

Learn more about this trial

Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

We'll reach out to this number within 24 hrs